Table 2.
Unadjusted and adjusted associations of serum phosphate and plasma FGF23 levels with retinopathy severity
| Hierarchical models | Phosphate odds ratio (95% CI) | P | FGF23 odds ratio (95% CI) | P |
|---|---|---|---|---|
| Univariable | 1.59 (1.43, 1.76) | <0.001 | 1.55 (1.40, 1.71) | <0.001 |
| + age, gender, race | 1.57 (1.42, 1.74) | <0.001 | 1.53 (1.38, 1.69) | <0.001 |
| + CVD, DM, A1c, HTN, SBP, BMI, smoking | 1.27 (1.13, 1.43) | <0.001 | 1.28 (1.14, 1.43) | <0.001 |
| + eGFR, ACR | 1.15 (1.02, 1.30) | 0.024 | 1.08 (0.95, 1.23) | 0.22 |
| + PTH, albumin, TC | 1.20 (1.05, 1.36) | 0.006 | 1.04 (0.92, 1.19) | 0.53 |
| + FGF23 or phosphate | 1.19 (1.05, 1.36) | 0.007 | 1.01 (0.89, 1.16) | 0.83 |
Results are reported as odds ratios per 1 standard deviation increase in serum phosphate and natural log-transformed FGF23.
CVD, cardiovascular disease; DM, diabetes mellitus; A1c; hemoglobin A1c; HTN, hypertension; SBP, systolic blood pressure; BMI, body mass index; eGFR, estimated glomerular filtration rate; ACR, albumin/creatinine ratio; PTH, parathyroid hormone; TC, total cholesterol; FGF23, fibroblast growth factor 23; CI, confidence interval.